Synergo for the treatment of
Non-Muscle Invasive Bladder Cancer
Powerful tri-modality of Radiofrequency-Induced Thermochemotherapy (RITE)
Improve Your Clinical Outcomes in NMIBC Management
Information for physicians about Synergo clinical indications, clinical and scientific trials and research, Synergo publications for Non-Muscle-Invasive Bladder Cancer, Recurrent NMIBC and BCG unresponsive patients
22.214.171.124.2.Device-assisted intravesical chemotherapy
Promising data have been presented on enhancing the efficacy of MMC using microwave-induced hyperthermia in patients with high-risk tumours . In one RCT comparing one year of BCG with one year MMC and microwave-induced hyperthermia in patients with intermediate- and high-risk BC, increased RFS at 24 months in the MMC group was demonstrated  (LE: 1b).
While clinical studies support the safety and effectiveness of the Synergo® RF thermo-chemotherapy system when used in the treatment of non-muscle invasive bladder cancer, results may vary. There are no guarantees of outcome. Before you decide on treatment options, discuss them with your doctor. Understanding the risks of each treatment can help you make the best decision for your individual situation. Synergo treatment may not be appropriate for every individual; it may not be applicable to your condition. Always ask your doctor about all treatment options, as well as their risks and benefits. Only your doctor can determine whether Synergo is appropriate for your situation. The information presented is not a substitute for the good advice of the attending physician. It is intended to supply patients with available information, thus making the doctor-patient dialogue more efficient: Legal Disclaimer